Recently, the USFDA approved the combination of Nivolumab and the first lymphocyte-activation gene 3 (LAG-3)-blocking antibody, Relatlimab (BMS986016), as treatment for patients with unresectable or metastatic melanoma (Table 7) (225). Here, LAG3 is linked to metastatic melanoma.